Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 8/20 | 0.66 |
| ▸ | CCND3 | P30281 | 5/20 | 0.66 |
| ▸ | CCND1 | P24385 | 4/20 | 0.66 |
| ▸ | CCND2 | P30279 | 4/20 | 0.66 |
| ▸ | EGFR | P00533 | 5/20 | 0.65 |
| ▸ | AURKA | O14965 | 4/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.60 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585855 | 0.89 | CDK4 (0.59) | CDK4CCND3CCND1CCND2EGFR | |
| SCHEMBL1353760 | 0.88 | EGFR (0.65) | CDK4CCND3CCND1CCND2EGFR | |
| SCHEMBL1355286 | 0.87 | CDK4 (0.59) | CDK4CCND3CCND1CCND2EGFR | |
| SCHEMBL1355798 | 0.87 | CDK4 (0.73) | CDK4CCND3CCND1CCND2EGFR | |
| SCHEMBL344502 | 0.87 | CDK4 (0.60) | CDK4CCND3CCND1CCND2FGFR4 | |
| SCHEMBL3571516 | 0.86 | EGFR (0.56) | CDK4CCND3CCND1CCND2EGFR | |
| SCHEMBL1355147 | 0.82 | TBK1 (0.61) | CDK4CCND3EGFRAURKAFGFR4 | |
| SCHEMBL18001919 | 0.81 | JAK3 (0.73) | EGFRSRCJAK2JAK3JAK1 | |
| SCHEMBL2585171 | 0.80 | EIF2AK4 (0.55) | CDK4CCND3CCND1CCND2ALK | |
| SCHEMBL1355345 | 0.80 | EGFR (0.51) | CDK4CCND3CCND1CCND2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | CDK4 71/4885CCND3 208/4885CCND1 272/4885 |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | CDK1, CDK2, CDK4 | CDK4 3/4885CCND3 43/4885CCND1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.